ImmunoGen Announces Multiple Presentations at AACR Annual Meeting

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that 11 posters highlighting continued innovation in the field of ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, Georgia.

“ImmunoGen remains at the forefront of ADC innovation and the data to be presented at AACR further demonstrate the value of our productive research platform,” said Richard Gregory, Ph.D., ImmunoGen’s chief scientific officer.

The schedule of ImmunoGen’s presentations at AACR is as follows:

IGN Payload Innovation

Title: Antibody-drug conjugates (ADCs) of a new class of N-10 amino linked DNA alkylating indolino-benzodiazepines (IGNs) – abstract #224
Date: March 31, 2019
Time: 1:00-5:00 PM ET

• In an ongoing effort to further explore the structure-activity relationship of DNA alkylating effector molecules for ADCs, a new class of IGNs has been developed that possesses a self-immolative peptide linker attached at the N-10 amine of the imine-reduced IGN monomer subunit. ADCs with this class of payload displayed potent, antigen-specific in vitro activity across a panel of folate receptor α (FRα)-expressing cell lines.

Title: Antibody-drug conjugates (ADCs) with indolinobenzodiazepine dimer (IGN) payloads: DNA-binding mechanism of IGN catabolites in target cancer cells - abstract #1886
Date: March 31, 2019
Time: 1:00-5:00 PM ET

• Investigation of the mechanism of binding of IGN catabolites with DNA in target cancer cells and with model duplex DNA or hairpin oligonucleotides. Both mono-and-di-imine IGN molecules remained bound to genomic DNA even at two days, suggesting a potent interaction with cellular DNA.

Advancement in Platform Linkers and Payloads

Title: Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers - abstract #0231
Date: March 31, 2019
Time: 1:00-5:00 PM ET

• Based on screens of a panel of dipeptide linkers for efficient lysosomal proteolysis, several novel, previously unreported peptide linker designs were identified and incorporated into ADCs bearing a DNA-alkylating IGN payload. Several dipeptide linker designs were superior in rates of lysosomal processing compared to a reference standard L-Ala-L-Ala dipeptide linker.

Title: LC-MS based catabolite identification study of an ADC with DM21-C, a novel maytansinoid linker-payload - abstract #538